Brexpiprazole

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Brexpiprazole
   1. Pharmacist Assessment Report
   2. Brexpiprazole: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Brexpiprazole: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Brexpiprazole, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own recorded uses, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	5
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
schizophrenia	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
anxiety disorder
endogenous depression
major depressive disorder
unipolar depression

Australia Market Information

Licence	Product	Dosage form	Status
11184P	Rexulti	Tablet 4 mg	Valid

Safety Considerations

• Drug Interactions: 100 interactions were identified in total. Those listed below are from the first 20 returned; the full list should be reviewed.
  • Major: bupropion, aprepitant, morphine, lorcaserin, cimetidine, clarithromycin, clotrimazole
  • Moderate: antidiabetic agents (acarbose, albiglutide, alogliptin, metformin, pioglitazone, canagliflozin, dapagliflozin, acetohexamide), epinephrine, and anticholinergics (hyoscyamine, atropine, clidinium), loperamide
• For warnings and contraindications, please refer to the TGA-approved Product Information (PI). Antipsychotics can cause dystonic reactions, which is particularly relevant if paediatric use were ever considered.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---